BIO (June 2024)/ XFTTBIOCMEGL / CME EMini
BIO2024-04-23 9:56:38 PM | Chg. +52.0000 | Bid10:02:02 PM | Ask10:02:02 PM | Open | High | Low | Previous Close |
---|---|---|---|---|---|---|---|
4,199.5000USD | +1.25% | - | - | 4,217.0000 | 4,221.0000 | 4,199.5000 | 4,147.5000 |
GlobeNewswire
1:00 PM
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...
GlobeNewswire
1:00 PM
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...
GlobeNewswire
04-24
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Stu...
GlobeNewswire
04-24
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of ...
GlobeNewswire
04-24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, I...
GlobeNewswire
04-24
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, I...
GlobeNewswire
04-24
Challenged Athletes Foundation and Össur Amplify Support for Athletes with Limb Loss and Limb Differ...
GlobeNewswire
04-24
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses o...
GlobeNewswire
04-24
noco-noco Collaborates with Binex to Develop Agriculture Based, Soil Sequestered Carbon into Credits
GlobeNewswire
04-23
BLUE INVESTOR NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages bluebird bio Inc. Investors to Inqui...
GlobeNewswire
04-23
Epic Bio Presents New Data Highlighting Potential of EPI-321 for FSHD and Epigenetic Editing Platfor...
GlobeNewswire
04-21
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Imp...
GlobeNewswire
04-19
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-M...
GlobeNewswire
04-18
ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Cla...
GlobeNewswire
04-18
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk...
GlobeNewswire
04-18
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under...
GlobeNewswire
04-18
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS...
GlobeNewswire
04-18
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinica...
GlobeNewswire
04-17
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Befor...